Wide Ranks

ATYR

aTyr Pharma, Inc.

3.44

Top Statistics
Market Cap 288 M Forward PE -4.24 Revenue Growth 0.00 %
Current Ratio 5.41 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.51 Enterprise / Revenue 1004.93 Price To Sales Trailing12 Months 1228.77
Profitability
Profit Margins 0.00 % Operating Margins -28958.72 %
Balance Sheet
Total Cash 65 M Total Cash Per Share 0.7860 Total Debt 13 M
Total Debt To Equity 20.83 Current Ratio 5.41 Book Value Per Share 0.8620
All Measures
Short Ratio 178.00 % Message Board Id finmb_33940575 Fax 858 731 8394
Shares Short Prior Month 1 M Return On Equity -0.7814 City San Diego
Uuid c1172678-0f95-38ea-bb85-c8424cf41867 Previous Close 3.29 First Trade Date Epoch Utc 1 B
Book Value 0.8620 Beta 1.10 Total Debt 13 M
Volume 717368 Price To Book 3.99 Last Split Date 1 B
Fifty Two Week Low 1.14 Total Cash Per Share 0.7860 Total Revenue 235000
Shares Short Previous Month Date 1 B Target Median Price 20.00 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Operating Margins -28958.72 %
Target Mean Price 21.29 Net Income To Common -63816000 Ask 3.47
Short Percent Of Float 0.0331 Implied Shares Outstanding 83 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 874460 Average Volume10days 874460
Total Cash 65 M Next Fiscal Year End 1 B Revenue Per Share 0.0030
Held Percent Insiders 0.0216 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 3.29 Target Low Price 9.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.69 Open 3.37
Free Cashflow -41668124 State CA Dividend Yield 0.00 %
Return On Assets -0.3926 Time Zone Short Name EST Trailing Eps -0.9400
Day Low 3.35 Address1 10240 Sorrento Valley Road Shares Outstanding 83 M
Price Hint 4 Target High Price 35.00 Website https://www.atyrpharma.com
52 Week Change 1.65 Average Volume 878787 Forward Eps -0.7900
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 480.40 %
Last Split Factor 1:14 Regular Market Day High 3.62 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 20.83 Fifty Two Week High 3.80
Day High 3.62 Shares Short 2 M Regular Market Open 3.37
Industry Key biotechnology Bid 3.40 Earnings Growth 0.00 %
Enterprise To Revenue 1004.93 Revenue Growth 0.00 % Shares Percent Shares Out 0.0252
Operating Cashflow -67049000 Currency USD Time Zone Full Name America/New_York
Market Cap 288 M Is_nasdaq_100 False Zip 92121
Quote Type EQUITY Industry Biotechnology Long Name aTyr Pharma, Inc.
Regular Market Day Low 3.35 Held Percent Institutions 0.6315 Current Price 3.44
Address2 Suite 300 Enterprise To Ebitda -3.51 Financial Currency USD
Current Ratio 5.41 Industry Disp Biotechnology Number Of Analyst Opinions 7
Country United States Float Shares 76 M Two Hundred Day Average 2.02
Enterprise Value 236 M Price To Sales Trailing12 Months 1228.77 Forward PE -4.24
Regular Market Volume 717368 Ebitda -67345000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States.

Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.

It has collaboration and license agreement with Kyorin Pharmaceutical Co.

, Ltd.

for the development and commercialization of efzofitimod for ILDs in Japan.

aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.